Clinical Trial Update: Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) [Phase 3]

View source ↗

Summary

Phase 3 trial update on immunogenicity and tolerability of a broad-spectrum HPV vaccine (V503-004) with completed status and results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• V503-004

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer, Vulvar Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-11-21